基于纳米技术的药物输送用于阿尔茨海默氏症和帕金森病
Phuong-Trang Nguyen-Thi1, Thanh-Tam Ho2,3, Thuy Trang Nguyen4
1Faculty of Pharmacy, HUTECH University, Ho Chi Minh City 700000, Vietnam.
Current drug delivery
|July 10, 2023
概括
纳米颗粒药物递送系统通过克服大脑障碍,显示出治疗中枢神经系统疾病的前景. 这篇评论探讨了阿尔茨海默氏症和帕金森症的纳米载体,强调了临床翻译的挑战.
科学领域:
- 神经科学是一个神经科学.
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 中枢神经系统 (CNS) 疾病由于血脑屏障等生物障碍,造成了治疗挑战.
- 纳米颗粒药物递送系统为克服这些障碍并提高治疗结果提供了一个有希望的策略.
- 脂质,聚合物和无机纳米载体正在积极研究中枢神经系统应用.
研究的目的:
- 审查和分类用于大脑药物输送的各种纳米载体.
- 讨论这些纳米载体在治疗阿尔茨海默氏症和帕金森病的潜力.
- 确定纳米粒子基础疗法的临床转化中的挑战.
主要方法:
- 文献综述和现有关于脑药物输送纳米载体的研究的综合.
- 基于材料组成 (脂质,聚合物,无机) 的纳米载体的分类.
- 讨论应用和临床翻译障碍.
主要成果:
- 纳米材料在穿越或绕过中枢神经系统障碍方面表现出显著的潜力.
- 目前正在探索各种纳米平台用于阿尔茨海默氏症和帕金森病治疗.
- 在将纳米粒子研究从实验室转化为临床实践方面仍然存在挑战.
结论:
- 纳米颗粒药物递送系统是中枢神经系统疾病治疗的可行方法.
- 需要进一步的研究来解决临床翻译的挑战,以便广泛应用.
- 纳米载体有望提高神经退行性疾病的治疗疗效.
相关概念视频
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Parkinson's Disease: Overview
604
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
604
Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
Parkinson's Disease: Treatment
302
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
302
siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Drug Delivery: Parenteral Route
633
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
633


